期刊
LEUKEMIA
卷 32, 期 3, 页码 752-764出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.316
关键词
-
资金
- National Institutes of Health [RO1-124929, P50-100007, PO1-78378, PO1155258, RO1-50947]
X-box binding protein 1 (XBP1), CD138 (Syndecan-1) and CS1 (SLAMF7) are highly expressed antigens in cancers including multiple myeloma (MM). Here, we identify and characterize immunogenic HLA-A24 peptides derived from these antigens for potential vaccination therapy of HLA-A24+ patients with MM. The identified immunogenic HLA-A24-specific XBP1 unspliced (UN)(185-193) (I S P W I L A V L), XBP1 spliced (SP)(223-231) (V Y P E G P S S L), CD138(265-273) (I F A V C L V G F) and CS1(240-248) (L F V L G L F L W) peptides induced antigen-specific CTL with anti-MM activity in an HLA-A24 restricted manner. Furthermore, a cocktail containing the four HLA-A24 peptides evoked MM-specific CTL with distinct phenotypic profiles (CD28, CD40L, 41BB, CD38, CD69) and anti-tumor activities, evidenced by perforin upregulation, CD107a degranulation (cytotoxicity) and Th1-type cytokines (IFN-gamma/IL-2/TNF-alpha) production in response to HLA-A24(+) MM cells. The multipeptide-specific CTL included antigen-specific memory CD8(+) T cells expressing both T-cell activation (CD38, CD69) and immune checkpoints antigens (CTLA, PD-1, LAG-3, TIM-3). These results provide the framework for a multipeptide vaccination therapy to induce tumor-specific CTL in HLA-A24-positive patients with myeloma and other cancers expressing these antigens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据